Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA
Abstract Hepatocellular carcinoma (HCC) is a highly malignant disease with a poor prognosis and high mortality due to a low early diagnosis rate, resistance to systemic treatments and progression to late-stage liver disease. Owing to limitations in the detection of HCC and the lack of awareness of h...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-09-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13046-018-0893-1 |
| _version_ | 1818265805792477184 |
|---|---|
| author | Jie Li Xu Han Xiaona Yu Zongzhen Xu Guangsheng Yang Bingqi Liu Peng Xiu |
| author_facet | Jie Li Xu Han Xiaona Yu Zongzhen Xu Guangsheng Yang Bingqi Liu Peng Xiu |
| author_sort | Jie Li |
| collection | DOAJ |
| description | Abstract Hepatocellular carcinoma (HCC) is a highly malignant disease with a poor prognosis and high mortality due to a low early diagnosis rate, resistance to systemic treatments and progression to late-stage liver disease. Owing to limitations in the detection of HCC and the lack of awareness of healthcare systems, fewer than 40% of HCC patients are eligible for surgery due to advanced stages of the disease at the time of diagnosis and the occurrence of multiple lesions in the cirrhotic or fibrotic liver. At present, the updated American Association for the Study of Liver Disease (AASLD) guidelines no longer recommend alpha-fetoprotein (AFP) testing as a part of diagnostic evaluation. Thus, it is imperative to establish a novel diagnostic strategy with high sensitivity and reliability to monitor risk factors to detect HCC at an early stage. In recent years, “liquid biopsy,” (including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA)), has emerged as a technique for the characterization of circulating cells, providing a strong basis for the individualized treatment of patients. As a noninvasive detection method, liquid biopsy is expected to play an important role in the early diagnosis, dynamic monitoring of cancer patients and drug screening. In this review, we will focus on the clinical applications, recent studies and future prospects of liquid biopsy, particularly focusing on HCC. |
| first_indexed | 2024-12-12T19:56:39Z |
| format | Article |
| id | doaj.art-9a618f44f928460d8e0cc2a929ffdfa2 |
| institution | Directory Open Access Journal |
| issn | 1756-9966 |
| language | English |
| last_indexed | 2024-12-12T19:56:39Z |
| publishDate | 2018-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj.art-9a618f44f928460d8e0cc2a929ffdfa22022-12-22T00:13:52ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662018-09-0137111310.1186/s13046-018-0893-1Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNAJie Li0Xu Han1Xiaona Yu2Zongzhen Xu3Guangsheng Yang4Bingqi Liu5Peng Xiu6Department of General Surgery, Shandong Provincial Qianfoshan Hospital, Shandong UniversityDepartment of Hepatobiliary Surgery, Zibo Central HospitalDepartment of General Medicine, Weifang Rongfu Military HospitalDepartment of General Surgery, Shandong Provincial Qianfoshan Hospital, Shandong UniversityDepartment of General Surgery, Shandong Provincial Qianfoshan Hospital, Shandong UniversityDepartment of General Surgery, Shandong Provincial Qianfoshan Hospital, Shandong UniversityDepartment of General Surgery, Shandong Provincial Qianfoshan Hospital, Shandong UniversityAbstract Hepatocellular carcinoma (HCC) is a highly malignant disease with a poor prognosis and high mortality due to a low early diagnosis rate, resistance to systemic treatments and progression to late-stage liver disease. Owing to limitations in the detection of HCC and the lack of awareness of healthcare systems, fewer than 40% of HCC patients are eligible for surgery due to advanced stages of the disease at the time of diagnosis and the occurrence of multiple lesions in the cirrhotic or fibrotic liver. At present, the updated American Association for the Study of Liver Disease (AASLD) guidelines no longer recommend alpha-fetoprotein (AFP) testing as a part of diagnostic evaluation. Thus, it is imperative to establish a novel diagnostic strategy with high sensitivity and reliability to monitor risk factors to detect HCC at an early stage. In recent years, “liquid biopsy,” (including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA)), has emerged as a technique for the characterization of circulating cells, providing a strong basis for the individualized treatment of patients. As a noninvasive detection method, liquid biopsy is expected to play an important role in the early diagnosis, dynamic monitoring of cancer patients and drug screening. In this review, we will focus on the clinical applications, recent studies and future prospects of liquid biopsy, particularly focusing on HCC.http://link.springer.com/article/10.1186/s13046-018-0893-1Hepatocellular carcinomaLiquid biopsyCirculating tumor cellsCirculating tumor DNA |
| spellingShingle | Jie Li Xu Han Xiaona Yu Zongzhen Xu Guangsheng Yang Bingqi Liu Peng Xiu Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA Journal of Experimental & Clinical Cancer Research Hepatocellular carcinoma Liquid biopsy Circulating tumor cells Circulating tumor DNA |
| title | Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA |
| title_full | Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA |
| title_fullStr | Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA |
| title_full_unstemmed | Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA |
| title_short | Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA |
| title_sort | clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma circulating tumor cells and circulating tumor dna |
| topic | Hepatocellular carcinoma Liquid biopsy Circulating tumor cells Circulating tumor DNA |
| url | http://link.springer.com/article/10.1186/s13046-018-0893-1 |
| work_keys_str_mv | AT jieli clinicalapplicationsofliquidbiopsyasprognosticandpredictivebiomarkersinhepatocellularcarcinomacirculatingtumorcellsandcirculatingtumordna AT xuhan clinicalapplicationsofliquidbiopsyasprognosticandpredictivebiomarkersinhepatocellularcarcinomacirculatingtumorcellsandcirculatingtumordna AT xiaonayu clinicalapplicationsofliquidbiopsyasprognosticandpredictivebiomarkersinhepatocellularcarcinomacirculatingtumorcellsandcirculatingtumordna AT zongzhenxu clinicalapplicationsofliquidbiopsyasprognosticandpredictivebiomarkersinhepatocellularcarcinomacirculatingtumorcellsandcirculatingtumordna AT guangshengyang clinicalapplicationsofliquidbiopsyasprognosticandpredictivebiomarkersinhepatocellularcarcinomacirculatingtumorcellsandcirculatingtumordna AT bingqiliu clinicalapplicationsofliquidbiopsyasprognosticandpredictivebiomarkersinhepatocellularcarcinomacirculatingtumorcellsandcirculatingtumordna AT pengxiu clinicalapplicationsofliquidbiopsyasprognosticandpredictivebiomarkersinhepatocellularcarcinomacirculatingtumorcellsandcirculatingtumordna |